The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Official Title: A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Study ID: NCT02595762
Brief Summary: This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Bank of Cyprus Oncology Center, Nicosia, , Cyprus
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, , Greece
Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, , Greece
ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, , Greece
251 Air Force General Hospital-Oncology Clinic, Athens, , Greece
Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, , Greece
IASO, Athens, , Greece
IASO General Hospital of Athens, Athens, , Greece
Attikon University Hospital; 4th Department of Internal Medicine, Haidari, , Greece
Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, , Greece
Theagenio Anticancer Hospital; 3Rd Oncology Clinic, Thessaloniki, , Greece
Papageorgiou General Hospital; Medical Oncology, Thessaloniki, , Greece
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR